Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lincoln Pharmaceuticals has informed that the Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 22, 2025 to consider and approve the audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2025 and recommendation of dividend on equity shares of the Company, if any, along with other business, if any. Further, in continuation to its disclosure on closure of trading window dated March 31, 2025, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2025 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.
The above information is a part of company’s filings submitted to BSE.
